Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JPMorgan Chase & Co. lowered shares of Adicet Bio (NASDAQ:ACET – Get Rating) from an overweight rating to a neutral rating in a research note published on Thursday morning, The Fly reports. JPMorgan Chase & Co. currently has $6.00 target price on the stock, down from their previous target price of $20.00. Other equities research […]
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to... | June 5, 2023
JPMorgan Chase & Co. cut shares of Adicet Bio (NASDAQ:ACET – Get Rating) from an overweight rating to a neutral rating in a report released on Thursday morning, The Fly reports. The brokerage currently has $6.00 price target on the stock, down from their prior price target of $20.00. A number of other equities analysts […]
CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.Results of the randomized phase 3 SWOG S1826 trial, presented at ASCO Annual Meeting, showed a 52% improvement in PFS with the nivolumab (Opdivo, Bristol Myers
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on May 31,... | May 31, 2023